loader
Page is loading...
generic_insight_detail


On Dec. 10, Lynn Tyler of the Indianapolis office spoke at the Food and Drug Law Institute's annual Enforcement, Litigation and Compliance conference in Washington, D.C. Lynn discussed the recent decision in Amarin Pharma, Inc. v. FDA, which is the most recent case to have relied on the First Amendment to deal a blow to the FDA's ban on the off-label promotion of drugs and medical devices. Lynn also discussed earlier cases addressing the same issue and practical considerations for companies confronting the issue.
Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.